This document is an excerpt from the EUR-Lex website
Document 52020M9855
Prior notification of a concentration (Case M.9855 – Onex/Independent Clinical Services) Candidate case for simplified procedure (Text with EEA relevance) 2020/C 219/11
Prior notification of a concentration (Case M.9855 – Onex/Independent Clinical Services) Candidate case for simplified procedure (Text with EEA relevance) 2020/C 219/11
Prior notification of a concentration (Case M.9855 – Onex/Independent Clinical Services) Candidate case for simplified procedure (Text with EEA relevance) 2020/C 219/11
PUB/2020/526
OJ C 219, 3.7.2020, p. 18–18
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
3.7.2020 |
EN |
Official Journal of the European Union |
C 219/18 |
Prior notification of a concentration
(Case M.9855 – Onex/Independent Clinical Services)
Candidate case for simplified procedure
(Text with EEA relevance)
(2020/C 219/11)
1.
On 24 June 2020, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).This notification concerns the following undertakings:
|
— |
Onex Corporation (‘Onex’, Canada), |
|
— |
Independent Clinical Services (United Kingdom), controlled by TowerBrook Capital Partners L.P. |
Onex acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Independent Clinical Services.
The concentration is accomplished by way of purchase of shares.
2.
The business activities of the undertakings concerned are:|
— |
for Onex: invests in various businesses worldwide including electronics manufacturing services, healthcare imaging, insurance services, packaging products and food retail and restaurants. |
|
— |
for Independent Clinical Services: provides workforce management solutions, health and social care services and staffing services to the healthcare, social care and life sciences sectors. It is present primarily in the United Kingdom and to a limited extent in the rest of Europe, the US and Asia-Pacific. |
3.
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.
4.
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.9855 – Onex/Independent Clinical Services
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu
Fax +32 22964301
Postal address:
|
European Commission |
|
Directorate-General for Competition |
|
Merger Registry |
|
1049 Bruxelles/Brussel |
|
BELGIQUE/BELGIË |
(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).